Group items matching

in title, tags, annotations or url

Infusion pumps have gained a lot of popularity in the medical community lately. The medical device is available in different varieties, depending on why you need to buy IV pumps.

Types of CP Associated With Muscle Tone Cerebral palsy comes in several types, which may be associated with muscle tone or specific body parts. Those associated with muscle tone include: spastic CP, where abnormally high muscle tone causes problems with movement, usually in the legs and hips; ataxia, which is marked by involuntary muscle movements; athetoid, which prevents sufferers from maintaining a fixed muscle position (for example, grasping and holding); and mixed, where symptoms of both spastic and athetoid CP occur. Cerebral Palsy: Hope Through Research: Detailed information from the National Institute of Neurological Disorders and Stroke, including facts on the causes, risk factors, warning signs, and types of CP. Definitions and Accommodations for Cerebral Palsy: Information on the types of CP and how to accommodate and interact with severe sufferers. From Kentucky's Office for the Americans With Disabilities Act. United Cerebral Palsy Association: Nonprofit organization that offers a nationwide network of affiliates aimed at expanding the rights, freedoms, and opportunities of those with cerebral palsy. Health Encyclopedia: Cerebral Palsy: Facts on the types, causes, prevalence, and accommodations related to cerebral palsy. Provided by the Florida Agency for Health Care Administration. Cost of Cerebral Palsy: Information on the human and economic impact of cerebral palsy, presented in the form of an academic report composed by the Environmental Protection Agency. Types of CP Associated With Body Parts Certain types of cerebral palsy are associated with specific body parts rather than with the general condition of the muscular system. These types include: quadriplegia, in which all four limbs suffer severe motor dysfunction and a general inability to work together; hemiplegia, in which the limbs on one side of the body are severely affected, with the impact more pronounced in the digits; and diplegia, which causes problems with mus

Refurbished B. Braun Outlook 100 Infusion IV Pump equipped with a color-coded key pad and audible key clicks, the safe, reliable and easy to use Outlook 100 infusion pump provides comprehensive "at-a-glance" viewing of infusion status on a large color display. Designed to help prevent IV medication administration errors, the Outlook 100 Safety Infusion Pump System's extensive customizable DoseGuard™ drug library allows you to configure the pump to match your clinical practice.

Refurbished Abbott Hospira Plum A+ Infusion Pump is a stationary multi-channel pump with software and display features that have been designed to reduce drug administration errors and help promote safe and on-time delivery of medications.

Refurbished Abbott Hospira Plum A+ Infusion Pump is a stationary multi-channel pump with software and display features that have been designed to reduce drug administration errors and help promote safe and on-time delivery of medications.

Social insurance industry ought to be changed and update with the time, Hms365cloud Systems is giving driving administrations development in this part of human services as Hospital Management System.

The US Food and Drug Administration (FDA) has approved the new Cochlear Nucleus Profile Plus Series Cochlear Implant and the Nucleus 7 Sound Processor's new built-in connectivity.

The US Food and Drug Administration (FDA) has issued a statement warning healthcare providers about potential complications in patients fitted with both programmable cerebrospinal fluid (CSF) shunt systems and certain magnetic hearing devices.

The Pharmacists' Defence Association (PDA) has issued an advisory information to community pharmacy contractors about Paxlovid antiviral treatment for non-hospitalised patients. "Patients will be assessed to see if they meet the criteria for inclusion and will need careful checking to see if Paxlovid therapy is safe due to the significant number of drug interactions. Assessment and prescribing are provided via dedicated services with dispensing and supply arranged by the central supply service or via participating community pharmacies," said the PDA. Every pharmacist can support this service by making themselves familiar with the service set up in their area. This is so that they can provide advice and signpost to healthcare colleagues and patients. Pharmacists working in general practice may also be able to help with identifying newly diagnosed highest risk patients. Whilst most of this group should have already been identified and contacted, no system is entirely foolproof. The PDA's advisory note provides information around indemnity and links to information about the prescribing and administration of Paxlovid since it is being provided under a temporary authorisation, and is subject to numerous drug-drug interactions, and is a recommended first-line treatment.

More than 10,000 pharmacy contractors those have declared their March FP34C submission figures through the Manage Your Service (MYS) portal by 5 April will receive earlier advance payments on Monday 11 April, the NHS Business Services Authority (NHSBSA) announced. Around 10,700 pharmacy contractors have made their submissions through MYS portal. They will receive their advance payments some 20 days earlier than the normal payment timetable. However, due to late submission (after April 5), over 500 contractors will not receive any earlier advance payments in April. These contractors will receive their advance payments on 1 May, in accordance with the normal payment timetable. From this month, MYS is the only route available to contractors for all monthly FP34C submissions. The Pharmaceutical Services Negotiating Committee (PSNC) reminded contractors that from this month (for prescriptions dispensed in March), the NHSBSA may apply an administrative deduction of £25 if a prescription bundle is submitted late.

Bambuterol 10mg tablet, used in the treatment of asthma and chronic obstructive pulmonary disease, is facing supply disruption as sole supplier of the medicine, Astra Zeneca, is discontinuing its production, according to an update by the Department of Health and Social Care (DHSC). The available stock of the medicine is expected to be exhausted by the end of June 2022. Meanwhile, other oral β2-agonists, which are the preferred route of administration, remain available, DHSC said.

Well Pharmacy has introduced a digital e-voucher platform for its corporate flu vaccination scheme. This platform simplifies the process of distributing flu vouchers to colleagues via email, employing individual flu voucher codes for each recipient, the company said in a statement. "Flu can disrupt business operations, especially during the bustling pre-Christmas period," said George Sandhu, Deputy Superintendent Pharmacist at Well Pharmacy. "Opting for staff flu jabs is a cost-effective means of safeguarding your business, employees, and their families. Our goal is to ensure a seamless setup, effortless administration, and convenient access to flu jabs for your colleagues, fitting into their schedules smoothly." According to the statement, Well Pharmacy's digital e-voucher platform offers effortless accessibility and various benefits, including swift email sharing, transparent upfront pricing and invoicing, and convenient tracking of voucher usage. Businesses can also track the utilisation and remaining availability of vouchers. "Just determine the desired number of vouchers and complete the order form," Sandhu added. "We'll provide a pre-filled agreement for your signature and return, along with an invoice. After setup, you'll receive a voucher code to distribute among your staff, along with promotional posters. They can access our website to obtain the necessary code for scheduling their vaccinations."

The Home Affairs Committee has called upon the government to revise its current drug policy, moving away from the exclusive 'abstinence only' approach towards a more practical strategy that highlights harm reduction. The HAC's recommendations also include the introduction of a national naloxone programme in England, with community pharmacies playing a central role in facilitating access. The committee published its comprehensive report on August 31, with key recommendations, including the 'urgent' reclassification of psychedelic drugs for therapeutic research; a pilot safe consumption facility program (long resisted by the Westminster Government despite Scottish lobbying); and enhanced provision and research on cannabis-based medicinal products (CBPMs). The report urged the establishment of a national naloxone programme in England, aligning with devolved nations. It also highlighted the role of community pharmacists and peer initiatives for effective distribution and administration. Furthermore, the report emphasises enhanced naloxone distribution for prison leavers. Naloxone is a medication capable of rapidly reversing heroin or methadone overdoses, potentially saving lives.

The International Pharmaceutical Federation (FIP) has offered a new resource to help countries self-assess readiness of their regulations to enable pharmacist-delivered vaccination services and, where needed, to implement such regulations. Developed by FIP's Regulators Advisory Group, it covers broad pharmacist-led roles related to vaccination from supply chain management to administration and prescribing. "This new resource from FIP is based on the experiences of professional regulators in countries where pharmacy-led vaccination has been successfully introduced and regulated. With it, we aim to support regulators, policymakers and national organisations in developing strategies or enabling regulatory frameworks in countries where the pharmacy workforce has a limited role in vaccination strategies so that it can contribute further to the global imperative of improving immunisation coverage," said Brett Simmonds, group chair. The "Pharmacy-led vaccination services: Regulatory self-assessment and implementation tool" aims to help identify strengths and areas for improvement in order to inform vaccination policy and planning efforts.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.

Millions of people take dietary supplements every day, hoping to improve their health in some way. But how much do you know about these supplements? Are they safe? Do they work? And are there any risks associated with taking them? Here are six important things to know about dietary supplements if you're one of the people who take them. NOT ALL SUPPLEMENTS ARE REGULATED Since dietary supplements are not drugs, they do not need to be approved by the Food and Drug Administration (FDA) before they can be sold. This means that some products may not contain what is stated on their labels or may even include ingredients that could be dangerous. Therefore, it's important to always read labels and do your research before committing to one. Furthermore, make sure you purchase your supplements from a reputable source. This means that you should look for companies that have been independently tested and certified to provide high-quality products. MAKE SURE THE SUPPLEMENT IS RIGHT FOR YOU Before taking any dietary supplement, check with your doctor or healthcare professional first. This is especially important if you have a medical condition or are on medication, as certain supplements may interact in unwanted ways. Just because something is labeled as "natural" doesn't necessarily mean it's good for you or that you even need to take it. Before taking any supplement, talk to your doctor about whether or not it could be beneficial for you and how much you should take.

The Royal Pharmaceutical Society (RPS) Scotland the BMA's Scottish GP Committee has called for improvements to the pharmacotherapy service. The joint statement released by the organisations on Friday (13 January), has recognised that much progress has been made but states that further improvements are needed to fully maximise the benefits of the service. It highlighted the need for better use of skill mix, including more clearly defining roles and responsibilities; improved IT enablers to reduce administrative burden; and further developing a tandem model of working comprising hubs with in-practice activity The two organisations state that inadequate funding and workforce shortages are a real threat to the pharmacotherapy service. They have urge Scottish Government to reconsider its recent decision to reduce funding for training pharmacy technicians. Clare Morrison, RPS Director for Scotland, said: "In the statement, we stress that the use of pharmacists' clinical skills must be maximised.

Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of January 18, 2023, the last trading day prior to today's announcement. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which is in late-stage development. It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.

Rowlands Pharmacy has joined hands with healthcare software company HasHealth for an enhanced digital proposition to facilitate seamless delivery of a raft of clinical services including flu and travel vaccinations. The new system is now available across 400 Rowlands pharmacies across the UK. The partnership comes as Rowlands Pharmacy strives to provide patients with a seamless booking experience whilst minimising time-consuming administration for pharmacy staff, with its waiting list, medical pre-screen questionnaires and resource management capabilities, the company said in a statement. HasHealth offers a virtual healthcare software solution that allows community pharmacies to schedule, manage, and communicate with patients easily online. It combines its cutting-edge video technology with booking and management software, which can be adapted to any clinical service. Nigel Swift, managing director at Rowlands Pharmacy, commented: "We pride ourselves on listening to our staff, based on feedback we knew we could do better with our digital proposition for clinical services and flu vaccinations in particular.

The Pharmaceutical Services Negotiating Committee (PSNC) has notified that it is now mandatory to attend face-to-face training for both injection technique and basic life support training periodically for pharmacists and other vaccinators providing the annual flu vaccination service. "Community pharmacy contractors are required to demonstrate that all vaccinators, including pharmacists, providing the flu vaccination service in their pharmacy have the skills needed to do so," said PSNC. Prior to this change, pharmacists and other vaccinators needed to undertake a refresher face-to-face training for both injection technique and basic life support, including administration of adrenaline, every three years. Vaccinator needs to evidence competence PSNC said: "Contractors and vaccinators will now need to consider when it would be appropriate to attend refresher training or if ongoing competence of an individual vaccinator can be evidenced, without the need for face-to-face training. "An individual's continued competence may be influenced by their prior experience vaccinating patients, including the overall number of vaccines administered and the regularity with which they administer vaccines."